Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology (Q37810697)

23 August 2017

Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology (English)

1 reference

23 August 2017

0 references

2

1 reference

23 August 2017

1

0 references

author name string

BAP Dementia Consensus Group

series ordinal

3

1 reference

PubMed ID

21088041

23 August 2017

language of work or name

English

0 references

publication date

18 November 2010

1 reference

Journal of Psychopharmacology

23 August 2017

1 reference

23 August 2017

25

1 reference

23 August 2017

8

1 reference

23 August 2017

997-1019

1 reference

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

23 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Galantamine treatment of vascular dementia: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Treatment of hypertension in patients 80 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Management of dementia with a cerebrovascular component

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Antidementia drugs: prescription by level of cognitive impairment or by socio-economic group?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Ginkgo biloba for prevention of dementia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Treatment of vascular risk factors is associated with slower decline in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A 6-month, open-label study of memantine in patients with frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Donepezil in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Huperzine A for vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Hormone replacement therapy to maintain cognitive function in women with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

EFNS guidelines for the diagnosis and management of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Donepezil for the treatment of agitation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Stimulant treatment of frontotemporal dementia in 8 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Education and use of dementia drugs: a register-based study of over 600,000 older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Frontotemporal dementia: a randomised, controlled trial with trazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Hormone replacement therapy for cognitive function in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Galantamine for Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Donepezil delays progression to AD in MCI subjects with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A feasibility and tolerability study of lithium in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Trazodone for agitation in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Modelling mini mental state examination changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Vascular factors predict rate of progression in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

The role of levodopa in the management of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Abeta species removal after abeta42 immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Role of imaging techniques in the diagnosis of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Absence of cholinergic deficits in "pure" vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Choline acetyltransferase activity in vascular dementia and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Memantine for behavioral disturbances in frontotemporal dementia: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Autonomic dysfunction in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

New approaches to the treatment of frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110387547

Ear drops for the removal of ear wax

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD004326

Identifiers

DOI

10.1177/0269881110387547

1 reference

23 August 2017

1 reference

PubMed ID

21088041